title: Tissue-specific expression of murine IP-10 mRNA following systemic treatment with interferon gamma.
abstract: We have examined the tissue distribution of 10-kd inflammatory protein (IP-10) mRNA expression in C57Bl/6 mice injected intravenously (i.v.) with various inflammatory stimuli. IP-10 mRNA was strongly induced by interferon-gamma (IFN-gamma) in liver and kidney but only poorly in skin, heart, and lung. IFN-gamma had nearly equivalent access to these tissues as indicated by the distribution of radiolabeled recombinant IFN-gamma 1 h after injection. The time course of IP-10 mRNA appearance was rapid and transient in both liver and kidney; maximal expression in the liver (2 h) preceded that in the kidney (3 h) and declined rapidly thereafter in both tissues. Expression of IP-10 mRNA in the liver and kidney was highly sensitive to IFN-gamma treatment; nearly maximal stimulation occurred with injection of 500 U of IFN-gamma per mouse. Comparable stimulation of IP-10 mRNA expression in splenic macrophages required 10,000 U of IFN-gamma administered i.v., indicating that liver and kidney responses are 10- to 20-fold more sensitive. IP-10 mRNA expression in both tissues was not restricted to stimulation by IFN-gamma but was also seen with injection of lipopolysaccharide (LPS) (25 micrograms/mouse) or IFN-beta (100,000 U/mouse). Two other members of the IP-10 gene family, KC (gro) and JE (MCP-1), were expressed at lower levels under similar treatment conditions. Analysis of IP-10 mRNA distribution in the liver and kidney by in situ hybridization indicated that expression in both tissues was most prominent in the reticuloendothelial cell system, particularly in the endothelial lining of the microvascular circulation. Although the function of the IP-10 gene product has not been defined, these results suggest that it may play an important role in the response of both the liver and kidney to systemic inflammation.
authors.affiliation: Research Institute, Cleveland Clinic Foundation, OH 44195.
authors.forename: S
authors.initials: S
authors.lastname: Narumi
authors.forename: L M
authors.initials: LM
authors.lastname: Wyner
authors.forename: M H
authors.initials: MH
authors.lastname: Stoler
authors.forename: C S
authors.initials: CS
authors.lastname: Tannenbaum
authors.forename: T A
authors.initials: TA
authors.lastname: Hamilton
mesh_terms: D000818:Animals; D054357:Chemokine CXCL10; D019743:Chemokines, CXC; D016207:Cytokines / Q000235:genetics*; D004305:Dose-Response Relationship, Drug; D015870:Gene Expression / Q000187:drug effects; D007249:Inflammation / Q000175:diagnosis; D007371:Interferon-gamma / Q000494:pharmacology; D007668:Kidney / Q000737:chemistry / Q000187:drug effects; D008070:Lipopolysaccharides / Q000008:administration & dosage; D008099:Liver / Q000737:chemistry / Q000187:drug effects; D051379:Mice; D008810:Mice, Inbred C57BL; D012157:Mononuclear Phagocyte System / Q000737:chemistry; D009693:Nucleic Acid Hybridization; D009928:Organ Specificity; D012333:RNA, Messenger / Q000032:analysis*
chemical_list: D054357:Chemokine CXCL10; D019743:Chemokines, CXC; D016207:Cytokines; D008070:Lipopolysaccharides; D012333:RNA, Messenger; D007371:Interferon-gamma